ABSTRACT
The objective of this study is to evaluate the effect of exhaled CO (eCO) on the development of asthma and allergic rhinitis (AR) by means of reviewing published literature. The literatures published between January 1997 and December 2008 from the US National Library of Medicine (NLM) Database were obtained according to inclusion criteria. Meta-analysis of randomized controlled trials (RCTs) was performed. CO levels of asthma and AR patients were compared with that of normal controls. HO-1(heme oxygenase-1) expression and effect of corticosteroids on eCO levels were also analyzed. Fifteen studies concerning asthma and four studies concerning AR were included in this analysis. Heterogeneity from different studies was evident (P < 0.0001), so a random-effects model was preferred. The meta-analysis revealed that asthmatic patients had significantly higher levels of eCO compared to normal controls. There was significant difference between asthma and control groups in terms of eCO (combined weighted mean difference (WMD) 1.33 (95% confidence interval 0.72 to 1.95), P < 0.0001), and no significant difference between AR and control (combined WMD 0.93 (95% confidence interval -0.54 to 2.40), P = 0.22). HO-1 expression were also reviewed, asthma group produced greater expression of HO-1 than control group with significant difference (combined standardized mean difference (SMD) 2.98 (95% confidence interval 1.13 to 4.84), P = 0.002). After corticosteroid therapy, significantly different levels of eCO were produced after corticosteroid therapy than did asthma group (combined WMD -1.23 (95% confidence interval -2.43 to -0.03), P = 0.04). The analysis reveals that eCO levels were significantly raised in asthma and it may attribute to high expression of HO-1, but there were no significantly high eCO levels between AR and control groups. Due to sensitivity to corticosteroid inhibition, eCO may be used as a practical marker to detect and monitor exacerbation of asthma.
Subject(s)
Biomarkers/analysis , Carbon Monoxide/analysis , Rhinitis, Allergic, Perennial/diagnosis , Rhinitis, Allergic, Perennial/physiopathology , Adolescent , Adrenal Cortex Hormones/therapeutic use , Adult , Asthma , Breath Tests , Child , Exhalation , Heme Oxygenase-1/metabolism , Humans , Middle Aged , Nasal Mucosa/metabolism , Nasal Mucosa/pathology , National Library of Medicine (U.S.) , Randomized Controlled Trials as Topic , Respiration/drug effects , Rhinitis, Allergic, Perennial/drug therapy , United StatesABSTRACT
To investigate the deletion of MTS1/p16 gene in human colorectal carcinoma,the homozygous deletion of MTS1/p16 gene was checked by reverse transcriptase polymerase chain reaction from 60 patients with colorectal carcinoma.The specimens consisted of 35 colorectal carcinoma,15 tumor-adjacent tissues and 10 normal colorectal mucosa. It was found that 17 14% (6/35) colorectal carcinoma specimens showed homozygous deletion of MTS1/p16 gene.No deletion was detected in tumor-adjacent tissue and normal colorectal mucosa.Deletion of MTS/p16 gene may play a role in the progression of colorectal carcinoma.
